INTRODUCTION
An important participant in the activation of human platelets is protein kinase C (PKC), which was discovered in 1977 by Nishizuka and his colleagues [1] . To date, 12 isoenzymes of PKC have been identified and classified into three groups: the conventional calcium-dependent cPKC (a, flu, fIl and y), the calcium-independent isoenzymes nPKC (d, e, and 6), and the atypical aPKC (C, A, t and It) [2] [3] [4] [5] [6] . To-date, six isoenzymes of PKC have been identified in human platelets [5, 7, 8] . One of the functions of PKC in platelets is to phosphorylate pleckstrin, a protein with a molecular mass of 40-47 kDa [9, 10] which has been implicated in the process of vesicular secretion [11] . The stimulation of PKC activity in platelets has been shown to occur following the addition of thrombin [12, 13] , adrenaline (epinephrine) [14] , platelet-activating factor (PAF) [15] , phorbol 12-myristate 13-acetate (PMA) [16, 17] and collagen [18, 19] . Recently, Crabos et al. [8] have demonstrated the translocation of PKC isoenzymes a, f, and C in human platelets stimulated by PMA. Baldassare et al. [7] have demonstrated the translocation of the PKC isoenzymes a, fi, a and C in platelets stimulated by thrombin. Our laboratory has confirmed the presence of cPKCa, cPKCfl, nPKC8 and aPKCC in human platelets and was the first to describe the presence of the PKC isoenzyme nPKCO in human platelets [20] . We have also identified a novel, high-molecularaddition of Mab.F1 1. The translocation from the cytoplasm to the membrane induced by Mab.FI 1 in PKC isoenzymes a and q was reversible, whereas translocation of the PKC isoenzymes 8, fl, y' and 0 was irreversible, with PKC levels remaining elevated in the membrane for at least 15 min. Taken together, our results demonstrate that in the initial stages of platelet activation by this stimulatory antibody, the enhanced membrane PKC activity reflects the presence of all six isoenzymes. At later stages, PKC activity is reflective offour isoenzymes. These results demonstrate that separate groups of PKC isoenzymes must be involved in different aspects of platelet activation. The long lag period and prolonged activation time of platelets by Mab.F1 1 renders this agonist most suitable for identifying the isoenzymes and their specific endogenous protein substrates involved in platelet secretion and aggregation induced by platelet membrane protein antibodies.
mass PKC isoenzyme, named nPKCy', of 95 kDa, using an antibody directed against the N-terminal of nPKCy [20] . We have reported that stimulation of human platelets by PAF resulted in a time-dependent translocation of nPKCy' and nPKCO from the cytosol to the plasma membrane [20] , suggesting that PKC isoenzymes q' and a play a role in the mechanism by which PAF activates platelets.
The presence ofautoantibodies directed against platelet surface proteins in the circulating plasma appears to play an important role in the pathophysiology of idiopathic thrombocytopenia purpura (ITP) [21] [22] [23] [24] and in thrombocytopenia associated with human immunodeficiency virus infections [25, 26] . Many of these circulating antibodies are stimulatory, as they induce platelet activation [21] [22] [23] [24] [25] [26] . The role of PKC isoenzymes in platelet activation by stimulatory antibodies has not yet been studied. Mab.Fl 1 is a stimulatory monoclonal antibody developed in our laboratory which recognizes a unique 32 kDa and 35 kDa protein duplex on the platelet surface, termed the Fl 1 receptor [27] . The partial sequence of the platelet F 11 receptor has been reported recently and PKC consensus sites were found in peptide fragments prepared both from endoproteinase Glu-C and trypsin digestion [28] . Furthermore, the phosphorylation of the isolated Fl 1 receptor was found to be stimulated by PMA and phosphatidylserine (PS), indicating the potential involvement of PKC in the down-regulation of this receptor [28] . 
Antibodies
The antibodies used were as follows: anti-cPKCa, polyclonal against peptide sequence 313AGNKVISPSEDRRQ326 (5 1ug/ml; Gibco); anti-cPKC fi, monoclonal antibody against the Nterminal regulatory domain (5 ,ug/ml; Seikagaku America Co.); and anti-cPKC,f, polyclonal against peptide sequence 661SYTNPEFVINV67' (5 jug/ml); anti-cPKCy, polyclonal against peptide sequence 306NYPLELYERVRTG318 (5 ,tg/ml; Gibco); anti-nPKC6, polyclonal against peptide sequence 664VNPKYEQFLE-COOH611 (1:100 dilution); kindly donated by Dr. Peter J. Parker, Imperial Cancer Research Fund, London); anti-nPKCe, polyclonal against peptide sequence 313KGFSYF-GEDLMP324 (5 ,tg/ml; Gibco); anti-aPKCC, polyclonal directed against peptide sequence 577GFEYINLLLSAEESV592 (5 ,tg/ml; Gibco); anti-nPKCy, polyclonal directed against the peptide sequence 56QTSTKQKTNKPTYNEEFC73 (3 ,g/ml) [29] ; and anti-nPKCO, polyclonal against the peptide sequence 332CVPT-PGKREPQGISWDSPLDGSNK355 (3,ug/ml) [30] . The characterization of Mab.Fl and Mab. GlO CaCl2 and the inhibitors heparin (2 units/ml), potato apyrase (320 /,g/ml) and PGE1(1 ,tM). Washed platelet pellets were resuspended in a Tyrode-Hepes solution without BSA or inhibitors and counted as described previously [20] .
Platelet aggregation
These experiments were performed in a Chronolog LumiAggregometer (Chronolog Corp., Havertown, PA, U.S.A.). Platelet aggregation was initiated by adding Mab.F1 1 (7 ,ug/ml) to 0.45 ml aliquots of PRP or washed platelet suspensions containing (2-4) x 108 platelets/ml incubated at 37°C under stirring conditions.
Assay of PKC activity In permeabilized cells
Washed platelets [(1.2-1.8) x 109 platelets/ml] were incubated at 37°C in Tyrode-Hepes buffer under non-stirring (or stirring) conditions in the presence or absence of Mab.F1 1. At various time points, aliquots were removed and centrifuged at 10000 g for 20 s. The platelet pellets were resuspended in 100 ll of PKC assay buffer following the procedure of Johnson and Heasley [31] with minor modifications. The buffer consisted of: 137 mM NaCl, 5.4 mM KCI, 0.3 mM NaH2PO4,H20, 0.4 mM KH2PO4, 1 mg/ml glucose, 20 mM Hepes (pH 7.2), 50 jug/ml digitonin, 10 mM MgCl2, 25 mM fl-glycerophosphate, 100 /uM [32P]ATP, 5 mM EGTA, 2.5 mM CaCl2, and 50 ,uM of the peptide PKC(19-3 1) Ser25. Kinase reactions proceeded at 30°C for 6 min, after which time the complete sample was spotted on to 2 cm x 2 cm phosphocellulose strips. The strips were washed in two changes of 1 % phosphoric acid and distilled water for five min each, placed in minivials containing 5 ml of scintillation fluid and counted in a beta scintillation counter. Endogenous phosphorylation measured in the absence of the peptide substrate was subtracted from all measurements.
Preparation of platelet membrane and cytosol fractions for immunoblotting Washed platelets (2 x 109/ml) were incubated with Mab.F1 1 (7 ,ug/ml) under non-stirring (or stirring) conditions at 37°C for various periods of time followed by the addition of an equal volume of cold double-concentrated sonication buffer containing: 20 mM Tris/HCl (pH 7.5), 2 mM EDTA, 50 mM f,-mercaptoethanol, lO mM EGTA, 1 mM PMSF, 5 #sg/ml leupeptin, 5 ,tg/ml trypsin inhibitor and 25 mM benzamidine as described previously [19] . The platelet suspensions were sonicated with three 10 s bursts and centrifuged at 100000 g for 30 min at 4°C using a Beckman TLA 100 ultracentrifuge (Beckman Instruments, Palo Alto, CA 94304, U.S.A.). The cytosol fractions were collected and the pelleted membrane fractions were resuspended in cold sonication buffer containing 1 % Triton X-100 (extraction buffer). The pellets were dispersed, sonicated and centrifuged at 100000 g for 30 min at 4 'C. The proteins extracted into the supernatants were removed as the membrane fraction. Protein concentration was determined by the method of Bradford [32] .
PKC assays of membrane fractions Aliquots of washed platelets (700 Il of 2 x 108 platelets) were incubated in an aggregometer under stirring (or non-stirring) conditions at 37 'C with Mab.F1 1 (7 ,ug/ml) for various lengths of time. Control aliquots were incubated for the same amount of time except without the prior addition of Mab.Fl 1. The platelet membranes were obtained as described above. PKC activity was assayed by measuring the incorporation of 32p from [y-32P]ATP into histone in membrane fractions as previously described [33] [34] [35] [36] with the following modifications. The reaction mixture (final volume, 100 ,ul) contained the following reagents: 25 mM Pipes (pH 7.0), 10 mM MgCl2, 0.2 mM DTT, 1 mM PMSF, 50 mM benzamidine, 25 ,tM CaCl2, leupeptin (10 ,ug/ml), trypsin inhibitor (50 ,tg/ml), PS (27 /sg/ml), diolein (2 /tg/ml) and histone (33 ,tg/ml). Reactions were initiated by the addition of [y-32P]ATP (final ATP concentration, 15 ,uM). Assays were carried out at 30°C using the above media in the absence or presence of PS and diolein for 5 min. The reactions were terminated by adding 1 ml of ice-cold 10% trichloroacetic acid containing 1.5 % sodium pyrophosphate and 1 % NaH2PO4(TCA solution). The samples were poured over filters (HA type) on a manifold (Millipore Corporation) and the filters were washed four times using the TCA solution. The filters were placed into scintillation vials to which 3 ml of scintillation fluid was added. The amount of radioactivity was measured using a Beckman LS6000TA liquid scintillation counter. PKC activity was determined by calculating the difference in the incorporation of 32P in the presence and absence of PS and diolein.
SOS/PAGE SDS/PAGE was performed using a 3 % stacking gel and an 8 % running gel as described by Laemmli [37] . Equal aliquots of 0.45 ml of cytosolic and membrane fractions from each time point were mixed with 100 ,ul of 6 x Laemmli sample buffer consisting of 62.5 mM Tris, 20% SDS, 10% glycerol, 50% ,-mercaptoethanol and 0.001 % Bromphenol Blue. Samples were vortexed, boiled for 5 min and applied to 3-cm-wide sample wells. The PKC isoenzymes V and 0, extracted from COS cells transfected with the nPKCO-and PKCy-cDNA expression plasmids, were used as positive controls. Proteins were transferred for 5 h at 4°C at 50 V on to nitrocellulose membranes (Schleicher & Schuell Co., 0.45 ,tm).
Immunoblotting
The nitrocellulose membranes were rinsed three times and incubated with 1 % BSA in TBST [50 mM Tris/HCl (pH 7.5), 0.15 M NaCl and 0.05 % Tween-20] for at least 2 h to block the non-specific binding of proteins to membranes. The membranes were cut into 3 mm strips and incubated with specific PKC isoenzyme antibodies. After overnight incubation with PKC antibodies at 4 0C, the nitrocellulose membranes were washed three times for 10 min with 1 % BSA in TBST. The membranes were incubated with alkaline phosphatase-conjugated anti-IgG antibody (Sigma Chemical Co.) for 2 h at 22 'C. The membranes were then washed five times in 1 % BSA in TBST, and immunoreactive bands were visualized by colour development using 0.41 M Nitro Blue Tetrazolium and 0.38 M 5-bromo 4-chloro-3-indolyl phosphate dissolved in 0.1 M Tris (pH 9.5)/0.1 M NaCl/5 mM MgC12.
Quantification of immunoblots
The densities of the PKC bands shown in the immunoblots were quantified using the XRS Omnimedia and Sharp scanners (XRS Omnimedia, and Sharp Co.) [23] Figure 1 . We observed that the latency period measured between the addition of antibody Mab.F1 1 and the initiation of aggregation was dependent on the concentration of Mab.F1 1 used. As shown in Figure 1 , Mab.FI 1 produced a latency period of approximately 3 min prior to the initiation of platelet aggregation. This latency period varied from donor to donor, indicating individual differences in sensitivity to this agonist. On the other hand, we consistently observed that the extent of platelet aggregation, measured in relative light transmission units, in response to Mab.FI 1 was greater than 60 % for each donor when platelets were isolated and washed following the centrifugation procedures described in the Materials and methods section.
To determine whether Mab.F1 1-induced platelet aggregation involves mechanisms associated with the activation of the fibrinogen receptor, we used an antibody shown by immunoblotting to recognize the GPIIIa component of the fibrinogen receptor. This antibody, Mab.G10, was reported previously to block the binding of fibrinogen to the platelet surface [27] . Preincubation of platelet suspensions with Mab.G10 completely blocked Mab.Fl l-induced platelet aggregation, as shown in Figure 1 ; indicative of the involvement of fibrinogen binding in the antibody-induced platelet aggregation process. As shown in Figure 3 Total platelet proteins, prepared from washed human platelets, were subjected to SDS/PAGE followed by immunoblotting. Nitrocellulose strips 'a' to 'iV and strip 'k' contain 50 #tg of protein/strip. Recombinant PKC isoenzymes (5 ,tg/strip) obtained from 00S cells transfected with nPKCq-cDNA and nPKCO-cDNA are shown as strips 'V' and 'j' respectively. Strips 'a', I'c', 'e', and 'g' were incubated with anti-PKCax, -/5, -8, and -~antibodies respectively. Strips i and 'j' were incubated with anti-PKCO, whereas strips 'k' and '1' were incubated with anti-PKC,q antibody. Strips 'b', 'd', 'f' and 'h' were incubated with anti-PKCcx, -/5, -&, and antibodies respectively, in the presence of their corresponding peptide (1 0 /ag/ml).
Identification of PKC isoenzymes in human platelets
To determine which PKC isoenzymes are responsible for the enhanced PKC activity associated with the platelet membrane following platelet activation by Mab.FlI 1, we initially sought to identify the presence of specific PKC isoenzymes in human platelets by use of anti-(PKC isoenzyme)-specific antibodies. We observed that six of the known PKC isoenzymes, namely az, /3, 6, , y' and 0 could be detected immunologically in human platelets (Figure 4) . The PKC isoenzymes e and y were not detectable in human platelets. The Washed human platelets were incubated with 7 ,ug/ml of Mab.F1 1 for the time periods showed above. Membrane and cytosol fractions were prepared and immunoblotting was performed as described in the Materials and methods section by using specific anti-PKC isoenzyme antibodies directed against cPKCa, cPKC,6, nPKC8, aPKCC, mPKCy, and nPKCO. and 80 kDa (doublet bands) for 0, and 95 kDa for y' (see Figure  4 , lanes a, c, e, g, i and k, respectively). The incubation of nitrocellulose strips with specific anti-PKC antibodies together with their corresponding peptides resulted in the complete disappearance of the staining of specific PKC protein bands (as 405 shown in Figure 4, As shown in Figure 5 , within 10 to 30 s of the addition of Mab.Fl 1, the levels of each of the six PKC isoenzymes investigated here increased significantly within the membrane, with a concurrent decrease in the level of PKC within the cytoplasm.
This rapid translocation to the membrane was maintained for either the entire length of time, as seen with PKC isoenzymes /, 8, q' and 0, or it was reversible, as shown for PKC isoenzymes a and g. We observed another consistent and significant increase in the level of PKCa within the membrane 15 min after the addition of Mab.F1 1. It is interesting to note that all of the PKC isoenzymes assayed here are present in detectable quantities in the platelet membrane prior to platelet activation. Among them, the levels of PKC isoenzymes a and a appear to be the highest (> 40 % of total), PKC isoenzymes~, 6 and y' in the membrane were found to be approximately 25 % of the total, whereas the level of PKC isoenzyme / (10 % of total) was the lowest of all.
DISCUSSION
In the study reported here we demonstrate directly that PKC activity is required for platelet activation by a stimulatory monoclonal antibody called Mab.Fl 1. The PKC activation by Mab.F 11 is accompanied by an increase in membrane-bound PKC activity and by a decrease in cytosolic PKC activity, suggesting translocation of PKC molecules. The pathway for PKC activation by the stimulatory antibody involves its initial interaction with the platelet surface protein recognized specifically by Mab.F 11, as well as interaction of Mab.F 11 with the platelet surface receptor for the Fc portion of immunoglobulins, FcyRII. This was determined by the finding that an antibody raised to the platelet FcyRII receptor blocked the Mab.F1 1 antibody-induced activation of PKC. Furthermore, the activation of PKC by Mab.F 11 appears to be mediated by a component of the platelet fibrinogen receptor, the GPIIIa molecule. Using a monoclonal antibody raised to the platelet surface glycoprotein GPIIIa, we have found that the platelet fibrinogen receptor is involved not only in fibrinogen binding and the production of extracellular fibrinogen bridges between aggregating platelets, but also plays a role in producing an intracellular signal that leads to the induction of secretion [27] . In the present study, using the same monoclonal antibody (termed GIO), we have found that the intracellular signal transduction pathway which is activated by the fibrinogen receptor leads to stimulation of PKC activity. The inhibition of PKC activation by Mab.IV.3 was not surprising, since it was previously shown that activation of human platelets by monoclonal antibodies that interact with the FcyRII receptor operates through a biochemical pathway that involves PKC [38, 39] . Nonetheless, the inhibition of PKC activation by Mab.GIO opens a new direction in studies investigating the biochemical events of platelet activation via a pathway that requires participation of the fibrinogen receptor.
Human platelets express PKC isoenzymes a, f6, 6, g, 6 and 1', but not PKC y and e [20] . In the present study, we have confirmed this report and determined, in addition, the redistribution of each PKC isoenzyme between the membrane and cytosol locations following platelet activation by Mab.Fl 1. It is accepted that measuring the redistribution of PKC activity evaluates the translocation of PKC molecules from the cytoplasm to the membrane [7, 8] . It should be mentioned, however, that the results of this assay do not exclude the possibility that enzyme activity in the cytoplasm decreases while other enzyme molecules, which are membrane-bound, are activated.
Several of the processes involved in platelet activation, in particular the exposure of fibrinogen receptors on the platelet surface, are likely to involve phosphorylation of membranebound proteins. However, the identity of the PKC isoenzymes that phosphorylate different membrane-bound platelet proteins is not yet known. Analysis of the time course of events following platelet activation demonstrated two different responses of PKC isoenzymes: a transient response was elicited by Mab.F1 I in the isoenzymes a and C and a sustained response was elicited by Mab.F1 1 in the PKC isoenzymes 8, /?, y' and 0. In comparison with other agonists, Baldassare et al. [7] found that thrombin could induce increased membrane-associated PKC a, , and g, while the subcellular distribution of PKC 6 remained unchanged. Crabos et al. [8] demonstrated that incubation of PMA with platelets resulted in greater translocation of PKC ,8 than a and C from the cytosol to the membrane. In the present study, we have found a different profile of activation of PKC isoenzymes, which may be related to the unique mechanism of activation of platelets by stimulatory antibodies.
The selective activation of various PKC isoenzymes, and the differing time course of activation and translocation following platelet stimulation by Mab.F1 1, suggest that stimulatory antibodies may activate different PKC isoenzymes which may then be involved in different aspects of platelet responsiveness, as compared with other agonists. Mab.F1 1 initially induces granular secretion followed by aggregation. It appears that the translocation of the PKC isoenzymes a and C to the membrane occurs primarily in the early stages of platelet activation by Mab.F1 1 (those events associated with a long latency), whereas the sustained association of PKC isoenzymes 6, fi, y' and 6 with the membrane is related to the later irreversible events involved in platelet secretion and aggregation. The prolonged lag-period and the extended time-course characteristic of platelet activation by Mab.F1 1 [27] have made this agonist most suitable for identifying the specific PKC isoenzymes involved in different aspects of platelet activation. Our future studies are designed to identify the endogenous protein substrate(s) for each of the specific PKC isoenzymes involved in the different phases of platelet function.
Circulating antibodies that stimulate platelet secretion and aggregation are known to be involved in the pathophysiology of disorders such as immune thrombocytopenia [21] [22] [23] [24] [25] [26] . Therefore, detailed elucidation of the biochemical pathways operating in the process of platelet activation by stimulatory antibodies is of great clinical significance and may serve in the development of novel therapeutic agents for the treatment of immunological diseases.
